[{"address1": "3805 Old Easton Road", "city": "Doylestown", "state": "PA", "zip": "18902", "country": "United States", "phone": "617 463 9385", "website": "https://www.aprea.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.", "fullTimeEmployees": 7, "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 4.07, "open": 4.295, "dayLow": 4.01, "dayHigh": 4.32, "regularMarketPreviousClose": 4.07, "regularMarketOpen": 4.295, "regularMarketDayLow": 4.01, "regularMarketDayHigh": 4.32, "beta": 1.979, "forwardPE": -5.141026, "volume": 39732, "regularMarketVolume": 39732, "averageVolume": 10206, "averageVolume10days": 16120, "averageDailyVolume10Day": 16120, "marketCap": 21775184, "fiftyTwoWeekLow": 2.78, "fiftyTwoWeekHigh": 8.847, "priceToSalesTrailing12Months": 22.593052, "fiftyDayAverage": 5.0749, "twoHundredDayAverage": 5.069485, "currency": "USD", "enterpriseValue": -9283748, "floatShares": 4012983, "sharesOutstanding": 5430220, "sharesShort": 32354, "sharesShortPriorMonth": 96178, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.006, "heldPercentInsiders": 0.11156999, "heldPercentInstitutions": 0.39953998, "shortRatio": 4.3, "shortPercentOfFloat": 0.008, "impliedSharesOutstanding": 5430220, "bookValue": 5.326, "priceToBook": 0.75291026, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12716957, "trailingEps": -3.28, "forwardEps": -0.78, "lastSplitFactor": "1:20", "lastSplitDate": 1676246400, "enterpriseToRevenue": -9.632, "enterpriseToEbitda": 0.664, "52WeekChange": 0.27099836, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "APRE", "underlyingSymbol": "APRE", "shortName": "Aprea Therapeutics, Inc.", "longName": "Aprea Therapeutics, Inc.", "firstTradeDateEpochUtc": 1570109400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9a8f76c4-98d0-37f2-b77b-05a35baa6936", "messageBoardId": "finmb_329831339", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.01, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.67, "targetMedianPrice": 16.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 32369972, "totalCashPerShare": 5.961, "ebitda": -13986331, "quickRatio": 10.917, "currentRatio": 11.153, "totalRevenue": 963800, "revenuePerShare": 0.25, "returnOnAssets": -0.2683, "returnOnEquity": -0.4383, "freeCashflow": -9262056, "operatingCashflow": -13134418, "operatingMargins": -8.27621, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]